Literature DB >> 19109547

Optimal Tmax threshold for predicting penumbral tissue in acute stroke.

Jean-Marc Olivot1, Michael Mlynash, Vincent N Thijs, Stephanie Kemp, Maarten G Lansberg, Lawrence Wechsler, Roland Bammer, Michael P Marks, Gregory W Albers.   

Abstract

BACKGROUND AND
PURPOSE: We sought to assess whether the volume of the ischemic penumbra can be estimated more accurately by altering the threshold selected for defining perfusion-weighting imaging (PWI) lesions.
METHODS: DEFUSE is a multicenter study in which consecutive acute stroke patients were treated with intravenous tissue-type plasminogen activator 3 to 6 hours after stroke onset. Magnetic resonance imaging scans were obtained before, 3 to 6 hours after, and 30 days after treatment. Baseline and posttreatment PWI volumes were defined according to increasing Tmax delay thresholds (>2, >4, >6, and >8 seconds). Penumbra salvage was defined as the difference between the baseline PWI lesion and the final infarct volume (30-day fluid-attenuated inversion recovery sequence). We hypothesized that the optimal PWI threshold would provide the strongest correlations between penumbra salvage volumes and various clinical and imaging-based outcomes.
RESULTS: Thirty-three patients met the inclusion criteria. The correlation between infarct growth and penumbra salvage volume was significantly better for PWI lesions defined by Tmax >6 seconds versus Tmax >2 seconds, as was the difference in median penumbra salvage volume in patients with a favorable versus an unfavorable clinical response. Among patients who did not experience early reperfusion, the Tmax >4 seconds threshold provided a more accurate prediction of final infarct volume than the >2 seconds threshold.
CONCLUSIONS: Defining PWI lesions based on a stricter Tmax threshold than the standard >2 seconds delay appears to provide more a reliable estimate of the volume of the ischemic penumbra in stroke patients imaged between 3 and 6 hours after symptom onset. A threshold between 4 and 6 seconds appears optimal for early identification of critically hypoperfused tissue.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19109547      PMCID: PMC2670783          DOI: 10.1161/STROKEAHA.108.526954

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  17 in total

1.  Ischemic injury detected by diffusion imaging 11 minutes after stroke.

Authors:  Niels Hjort; Søren Christensen; Christine Sølling; Mahmoud Ashkanian; Ona Wu; Lisbeth Røhl; Carsten Gyldensted; Grethe Andersen; Leif Østergaard
Journal:  Ann Neurol       Date:  2005-09       Impact factor: 10.422

Review 2.  How healthy is the acutely reperfused ischemic penumbra?

Authors:  J-C Baron
Journal:  Cerebrovasc Dis       Date:  2005-12-02       Impact factor: 2.762

3.  Spontaneous neurological recovery after stroke and the fate of the ischemic penumbra.

Authors:  M Furlan; G Marchal; F Viader; J M Derlon; J C Baron
Journal:  Ann Neurol       Date:  1996-08       Impact factor: 10.422

4.  Relationship between severity of MR perfusion deficit and DWI lesion evolution.

Authors:  V N Thijs; A Adami; T Neumann-Haefelin; M E Moseley; M P Marks; G W Albers
Journal:  Neurology       Date:  2001-10-09       Impact factor: 9.910

5.  Thresholds in cerebral ischemia - the ischemic penumbra.

Authors:  J Astrup; B K Siesjö; L Symon
Journal:  Stroke       Date:  1981 Nov-Dec       Impact factor: 7.914

6.  Diffusion-weighted MR imaging of acute stroke: correlation with T2-weighted and magnetic susceptibility-enhanced MR imaging in cats.

Authors:  M E Moseley; J Kucharczyk; J Mintorovitch; Y Cohen; J Kurhanewicz; N Derugin; H Asgari; D Norman
Journal:  AJNR Am J Neuroradiol       Date:  1990-05       Impact factor: 3.825

7.  Perfusion-weighted magnetic resonance imaging thresholds identifying core, irreversibly infarcted tissue.

Authors:  Ludy C Shih; Jeffrey L Saver; Jeffry R Alger; Sidney Starkman; Megan C Leary; Fernando Vinuela; Gary Duckwiler; Y Pierre Gobin; Reza Jahan; J Pablo Villablanca; Paul M Vespa; Chelsea S Kidwell
Journal:  Stroke       Date:  2003-05-08       Impact factor: 7.914

8.  Relationships between infarct growth, clinical outcome, and early recanalization in diffusion and perfusion imaging for understanding stroke evolution (DEFUSE).

Authors:  Jean-Marc Olivot; Michael Mlynash; Vincent N Thijs; Stephanie Kemp; Maarten G Lansberg; Lawrence Wechsler; Gottfried Schlaug; Roland Bammer; Michael P Marks; Gregory W Albers
Journal:  Stroke       Date:  2008-06-19       Impact factor: 7.914

Review 9.  Beyond mismatch: evolving paradigms in imaging the ischemic penumbra with multimodal magnetic resonance imaging.

Authors:  Chelsea S Kidwell; Jeffry R Alger; Jeffrey L Saver
Journal:  Stroke       Date:  2003-10-23       Impact factor: 7.914

Review 10.  Viability thresholds and the penumbra of focal ischemia.

Authors:  K A Hossmann
Journal:  Ann Neurol       Date:  1994-10       Impact factor: 10.422

View more
  110 in total

1.  Perfusion CT in acute ischemic stroke: a qualitative and quantitative comparison of deconvolution and maximum slope approach.

Authors:  B Abels; E Klotz; B F Tomandl; S P Kloska; M M Lell
Journal:  AJNR Am J Neuroradiol       Date:  2010-06-25       Impact factor: 3.825

2.  Angiographic outcome of endovascular stroke therapy correlated with MR findings, infarct growth, and clinical outcome in the DEFUSE 2 trial.

Authors:  Michael P Marks; Maarten G Lansberg; Michael Mlynash; Stephanie Kemp; Ryan A McTaggart; Greg Zaharchuk; Roland Bammer; Gregory W Albers
Journal:  Int J Stroke       Date:  2014-03-31       Impact factor: 5.266

Review 3.  Real-time diffusion-perfusion mismatch analysis in acute stroke.

Authors:  Matus Straka; Gregory W Albers; Roland Bammer
Journal:  J Magn Reson Imaging       Date:  2010-11       Impact factor: 4.813

4.  RAPID automated patient selection for reperfusion therapy: a pooled analysis of the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) and the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) Study.

Authors:  Maarten G Lansberg; Jun Lee; Soren Christensen; Matus Straka; Deidre A De Silva; Michael Mlynash; Bruce C Campbell; Roland Bammer; Jean-Marc Olivot; Patricia Desmond; Stephen M Davis; Geoffrey A Donnan; Gregory W Albers
Journal:  Stroke       Date:  2011-04-14       Impact factor: 7.914

5.  Imaging of experimental stroke models.

Authors:  Marc Fisher; Bernt Tore Bråtane
Journal:  Transl Stroke Res       Date:  2011-11-15       Impact factor: 6.829

6.  Arterial spin labeling for acute stroke: practical considerations.

Authors:  Greg Zaharchuk
Journal:  Transl Stroke Res       Date:  2012-04-14       Impact factor: 6.829

7.  Relationships between cerebral perfusion and reversibility of acute diffusion lesions in DEFUSE: insights from RADAR.

Authors:  Jean-Marc Olivot; Michael Mlynash; Vincent N Thijs; Archana Purushotham; Stephanie Kemp; Maarten G Lansberg; Lawrence Wechsler; Roland Bammer; Michael P Marks; Gregory W Albers
Journal:  Stroke       Date:  2009-03-19       Impact factor: 7.914

8.  Accuracy and reliability assessment of CT and MR perfusion analysis software using a digital phantom.

Authors:  Kohsuke Kudo; Soren Christensen; Makoto Sasaki; Leif Østergaard; Hiroki Shirato; Kuniaki Ogasawara; Max Wintermark; Steven Warach
Journal:  Radiology       Date:  2012-12-06       Impact factor: 11.105

Review 9.  Use of magnetic resonance imaging to predict outcome after stroke: a review of experimental and clinical evidence.

Authors:  Tracy D Farr; Susanne Wegener
Journal:  J Cereb Blood Flow Metab       Date:  2010-01-20       Impact factor: 6.200

10.  Pretreatment diffusion- and perfusion-MR lesion volumes have a crucial influence on clinical response to stroke thrombolysis.

Authors:  Mark W Parsons; Soren Christensen; Patrick McElduff; Christopher R Levi; Ken S Butcher; Deidre A De Silva; Martin Ebinger; P Alan Barber; Christopher Bladin; Geoffrey A Donnan; Stephen M Davis
Journal:  J Cereb Blood Flow Metab       Date:  2010-01-20       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.